Polypid Stock Today
| PYPD Stock | USD 4.30 0.05 1.18% |
PerformanceMild
| Odds Of DistressStrong
|
PolyPid is trading at 4.30 as of the 2nd of March 2026, a 1.18 percent increase since the beginning of the trading day. The stock's lowest day price was 4.16. PolyPid has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 2nd of December 2025 and ending today, the 2nd of March 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of June 2020 | Category Healthcare | Classification Health Care |
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform to address unmet medical needs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. The company has 18.2 M outstanding shares of which 30.37 K shares are at this time shorted by private and institutional investors with about 0.45 trading days to cover. More on PolyPid
Moving together with PolyPid Stock
Moving against PolyPid Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
PolyPid Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, PolyPid can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on PolyPid's use of financial leverage and reveals what portion of PolyPid's asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||
PolyPid (PYPD) is traded on NASDAQ Exchange in USA and employs 57 people. PolyPid is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 77.37 M. PolyPid conducts business under Biotechnology sector and is part of Health Care industry. The entity has 18.2 M outstanding shares of which 30.37 K shares are at this time shorted by private and institutional investors with about 0.45 trading days to cover.
PolyPid currently holds about 23.78 M in cash with (21.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Check PolyPid Probability Of Bankruptcy
Ownership AllocationPolyPid owns a total of 18.2 Million outstanding shares. 30% of PolyPid outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check PolyPid Ownership Details
PolyPid Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bnp Paribas Arbitrage, Sa | 2025-12-31 | 9.3 K | |
| Steward Partners Investment Advisory, Llc | 2025-09-30 | 7.3 K | |
| Northwestern Mutual Wealth Management Co | 2025-09-30 | 4 K | |
| Ubs Group Ag | 2025-09-30 | 1 K | |
| Jpmorgan Chase & Co | 2025-09-30 | 870 | |
| Advisor Group Holdings, Inc. | 2025-09-30 | 467 | |
| Sbi Securities Co Ltd | 2025-09-30 | 2.0 | |
| Citadel Advisors Llc | 2025-09-30 | 0.0 | |
| Aigh Capital Management, Llc | 2025-12-31 | 1.3 M | |
| Rosalind Advisors, Inc. | 2025-12-31 | 696.6 K | |
| Dafna Capital Management Llc | 2025-12-31 | 207.9 K |
PolyPid Historical Income Statement
PolyPid Stock Against Markets
PolyPid Corporate Management
| Ori Warshavsky | Chief US | Profile | |
| MD MBA | Chief Officer | Profile | |
| Dikla Akselbrad | Chief Officer | Profile | |
| Malka Reichart | Scientific Director | Profile | |
| Rivi Levari | Vice Resource | Profile | |
| Orna Blum | Legal Counsel | Profile | |
| JeanMarc PharmD | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PolyPid. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could PolyPid diversify its offerings? Factors like these will boost the valuation of PolyPid. Anticipated expansion of PolyPid directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every PolyPid data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of PolyPid is measured differently than its book value, which is the value of PolyPid that is recorded on the company's balance sheet. Investors also form their own opinion of PolyPid's value that differs from its market value or its book value, called intrinsic value, which is PolyPid's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because PolyPid's market value can be influenced by many factors that don't directly affect PolyPid's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between PolyPid's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PolyPid should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, PolyPid's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.